publication . Article . 2013

Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure

Prats, Merche; Font, Ramon; García-Ruiz, Carmen; Cabré, Carmen; Muñoz-Cortés, Mónica; Nogués, M. Rosa; Jariod, Manel; Romeu, Marta; Martínez-Vea, Alberto;
Open Access Spanish
  • Published: 01 Jan 2013
  • Publisher: Sociedad Española de Nefrología
Abstract
Antecedentes: El tratamiento con hierro parenteral provoca estrés oxidativo, inflamación y disfunción endotelial. La carboximaltosa férrica (CMF) es un nuevo preparado de hierro no dextrano que, por sus características farmacocinéticas y estabilidad, podría inducir menor toxicidad que otras moléculas de hierro. El objetivo de este estudio fue analizar el efecto de la CMF sobre la inflamación y moléculas de adhesión en la enfermedad renal crónica (ERC). Métodos: Cuarenta y siete pacientes con ERC prediálisis y anemia ferropénica recibieron una dosis única de CMF (15 mg/kg, dosis máxima 1 gramo). De forma basal, a los 60 minutos (efecto agudo), y a las 3 semanas y...
Subjects
free text keywords: Carboximaltosa férrica, Chronic renal failure, Inflammation, Adhesion molecules, Inflamación, Moléculas de adhesión, Insuficiencia renal crónica, Ferric carboxymaltose
36 references, page 1 of 3

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401.

2. Akins PT, Glenn S, Nemeth PM, Derdeyn CP. Carotid artery thrombus associated with severe iron deficiency anemia and thrombocytosis. Stroke 1996;27:1002-5.

3. Hartfield DS, Lowry NJ, Keene DL, Yager JY. Iron deficiency: a cause of stroke in infants and children. Pediatr Neurol 1997;16:50-3.

4. De Caterina R, Basta G, Lazzerini G, Dell'Omo G, Petrucci R, Morale M. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2646-54.

5. Suliman M, Qureshi R, Heimburger O, Lindholm B, Stenvinkel P. Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. Nephrol Dial Transplant 2006;21:1603-10.

6. Stinghen AE, Gonçalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract 2009;111:c117-26.

7. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16 Suppl 1:S83-8.

8. Yuksel A, Kebapcilar L, Erdur E, Bozkaya G, Sari I, Alacacioglu A, et al. The Effect of iron treatment on adhesion molecules in patients with iron deficiency anemia. Biol Trace Elem Res 2010;137:317-23.

9. Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 2006;69:1259-63.

10. Kamanna VS, Ganji SH, Shelkovnikov S, Norris K, Vaziri ND. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol 2012;35:114-9.

11. Jairam A, Das R, Aggarwal PK, Kohli HS, Gupta KL, Sakhuja V, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J Nephrol 2010;20:125-31.

12. Malindretos P, Sarafidis PA, Rudenco I, Raptis V, Makedou K, Makedou A, et al. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Am J Nephrol 2007;27:572-9.

13. Borawski J, Gozdzikiewicz J, Abramowicz P, Naumnik B, Mysliwiec M. Endothelial injury markers with high-dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost 2004;10:403-6.

14. Kumbasar A, Gursu M, Kaya C, Ozturk S, Ergen A, Kemik A, et al. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients. J Nephrol 2012;25(5):825-32.

15. Bolaños L, González-Juanatey C, Testa A, Ranero R. Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients. Adv Perit Dial 2008;24:90-5.

36 references, page 1 of 3
Abstract
Antecedentes: El tratamiento con hierro parenteral provoca estrés oxidativo, inflamación y disfunción endotelial. La carboximaltosa férrica (CMF) es un nuevo preparado de hierro no dextrano que, por sus características farmacocinéticas y estabilidad, podría inducir menor toxicidad que otras moléculas de hierro. El objetivo de este estudio fue analizar el efecto de la CMF sobre la inflamación y moléculas de adhesión en la enfermedad renal crónica (ERC). Métodos: Cuarenta y siete pacientes con ERC prediálisis y anemia ferropénica recibieron una dosis única de CMF (15 mg/kg, dosis máxima 1 gramo). De forma basal, a los 60 minutos (efecto agudo), y a las 3 semanas y...
Subjects
free text keywords: Carboximaltosa férrica, Chronic renal failure, Inflammation, Adhesion molecules, Inflamación, Moléculas de adhesión, Insuficiencia renal crónica, Ferric carboxymaltose
36 references, page 1 of 3

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401.

2. Akins PT, Glenn S, Nemeth PM, Derdeyn CP. Carotid artery thrombus associated with severe iron deficiency anemia and thrombocytosis. Stroke 1996;27:1002-5.

3. Hartfield DS, Lowry NJ, Keene DL, Yager JY. Iron deficiency: a cause of stroke in infants and children. Pediatr Neurol 1997;16:50-3.

4. De Caterina R, Basta G, Lazzerini G, Dell'Omo G, Petrucci R, Morale M. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2646-54.

5. Suliman M, Qureshi R, Heimburger O, Lindholm B, Stenvinkel P. Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. Nephrol Dial Transplant 2006;21:1603-10.

6. Stinghen AE, Gonçalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract 2009;111:c117-26.

7. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16 Suppl 1:S83-8.

8. Yuksel A, Kebapcilar L, Erdur E, Bozkaya G, Sari I, Alacacioglu A, et al. The Effect of iron treatment on adhesion molecules in patients with iron deficiency anemia. Biol Trace Elem Res 2010;137:317-23.

9. Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 2006;69:1259-63.

10. Kamanna VS, Ganji SH, Shelkovnikov S, Norris K, Vaziri ND. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol 2012;35:114-9.

11. Jairam A, Das R, Aggarwal PK, Kohli HS, Gupta KL, Sakhuja V, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J Nephrol 2010;20:125-31.

12. Malindretos P, Sarafidis PA, Rudenco I, Raptis V, Makedou K, Makedou A, et al. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Am J Nephrol 2007;27:572-9.

13. Borawski J, Gozdzikiewicz J, Abramowicz P, Naumnik B, Mysliwiec M. Endothelial injury markers with high-dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost 2004;10:403-6.

14. Kumbasar A, Gursu M, Kaya C, Ozturk S, Ergen A, Kemik A, et al. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients. J Nephrol 2012;25(5):825-32.

15. Bolaños L, González-Juanatey C, Testa A, Ranero R. Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients. Adv Perit Dial 2008;24:90-5.

36 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue